Radiation Therapy Targeted For More Medicare Cuts
This article was originally published in The Gray Sheet
Executive Summary
CMS says the large, protective vaults constructed to house the linear accelerators necessary for radiation therapy represent a building cost, not a medical equipment cost, and, thus, overall reimbursement for the treatments should be reduced.
You may also be interested in...
Oncology Society Proposes Changes To Radiation Therapy Procedure Codes
ASTRO proposes redesign of key radiation therapy codes as first part of its Payment Reform Action Plan.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.